Biogen’s SKYCLARYS Formulation Study: What a New Liquid Tablet Could Mean for BIIB Investors

Biogen Inc. (BIIB) announced an update on their ongoing clinical study.

Biogen Inc. (BIIB) is running a Phase 1 study called “A Phase 1, Randomized, Open-Label, Single-Dose, Crossover, Bioequivalence Study of Omaveloxolone Tablets for Oral Suspension Versus Capsules in Healthy Adult Participants.” The aim is to see if its rare disease drug BIIB141, sold as SKYCLARYS, works the same in the body when taken as a liquid tablet versus the current capsule form, which matters for long term patient use and market reach.

The study tests omaveloxolone, also known as BIIB141 or SKYCLARYS. It compares a new tablet that dissolves in liquid against the approved capsule form to make treatment easier for people who struggle to swallow pills while keeping drug exposure similar.

The trial is interventional and randomized, so healthy adults are assigned by chance to different dose orders. It uses a two way crossover design without blinding, meaning each person gets both the capsule and the liquid tablet at different times, and the main goal is to compare how the body absorbs and clears the two forms and watch for safety issues.

The study uses two sequences, with one group getting capsules first and liquid tablets later and the other group in reverse order. Each person stays on study for up to 57 days, with about 14 days between doses, and the research team takes blood and urine samples along the way to track drug levels and health checks.

The trial was first submitted on 9 December 2025, marking the formal start of regulatory tracking. The last update was filed on 13 May 2026, which shows Biogen is still maintaining current information on the study status and data.

As a Phase 1 bioequivalence study in healthy volunteers, this dataset will not change revenue near term but could support a label or formulation expansion for SKYCLARYS. A flexible liquid tablet form may improve adherence, extend the product life cycle, and strengthen Biogen’s position in Friedreich’s ataxia against present and future rare disease rivals.

Investors may see this update as a modest but positive sign that Biogen is investing in patient friendly formats for an existing asset rather than only relying on new drugs. While the headline stock impact is likely small versus large pipeline events, better usability can support sustained pricing power and help defend share in a niche but strategic neurology market.

This study is now updated and continues to inform Biogen’s formulation strategy, with further details available on the ClinicalTrials portal.

To learn more about BIIB’s potential, visit the Biogen Inc. drug pipeline page.